Home > Publications database > Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review. > print

001     178459
005     20240229133806.0
024 7 _ |2 doi
|a 10.3390/jcm11010124
024 7 _ |2 pmid
|a pmid:35011868
024 7 _ |a altmetric:120817891
|2 altmetric
037 _ _ |a DKFZ-2022-00085
041 _ _ |a English
082 _ _ |a 610
100 1 _ |0 0000-0001-8615-5393
|a Voellger, Benjamin
|b 0
245 _ _ |a Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review.
260 _ _ |a Basel
|b MDPI
|c 2021
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1642060113_474
|x Review Article
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a Pituitary adenomas (PAs) are mostly benign endocrine tumors that can be treated by resection or medication. However, up to 10% of PAs show an aggressive behavior with invasion of adjacent tissue, rapid proliferation, or recurrence. Here, we provide an overview of target structures in aggressive PAs and summarize current clinical trials including, but not limited to, PAs. Mainly, drug targets in PAs are based on general features of tumor cells such as immune checkpoints, so that programmed cell death 1 (ligand 1) (PD-1/PD-L1) targeting may bear potential to cure aggressive PAs. In addition, epidermal growth factor receptor (EGFR), mammalian target of rapamycin (mTOR), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and their downstream pathways are triggered in PAs, thereby modulating tumor cell proliferation, migration and/or tumor angiogenesis. Temozolomide (TMZ) can be an effective treatment of aggressive PAs. Combination of TMZ with 5-Fluorouracil (5-FU) or with radiotherapy could strengthen the therapeutic effects as compared to TMZ alone. Dopamine agonists (DAs) are the first line treatment for prolactinomas. Dopamine receptors are also expressed in other subtypes of PAs which renders Das potentially suitable to treat other subtypes of PAs. Furthermore, targeting the invasive behavior of PAs could improve therapy. In this regard, human matrix metalloproteinase (MMP) family members and estrogens receptors (ERs) are highly expressed in aggressive PAs, and numerous studies demonstrated the role of these proteins to modulate invasiveness of PAs. This leaves a number of treatment options for aggressive PAs as reviewed here.
536 _ _ |0 G:(DE-HGF)POF4-312
|a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |2 Other
|a adjuvant treatment
650 _ 7 |2 Other
|a hormone secretion
650 _ 7 |2 Other
|a invasiveness
650 _ 7 |2 Other
|a molecular biology
650 _ 7 |2 Other
|a pituitary adenomas
650 _ 7 |2 Other
|a proliferation
700 1 _ |a Zhang, Zhuo
|b 1
700 1 _ |0 P:(DE-He78)2b12a7cfc604eb9816670e995f7af508
|a Benzel, Julia
|b 2
|u dkfz
700 1 _ |a Wang, Junwen
|b 3
700 1 _ |a Lei, Ting
|b 4
700 1 _ |a Nimsky, Christopher
|b 5
700 1 _ |0 0000-0002-2773-3357
|a Bartsch, Jörg-Walter
|b 6
773 _ _ |0 PERI:(DE-600)2662592-1
|a 10.3390/jcm11010124
|g Vol. 11, no. 1, p. 124 -
|n 1
|p 124
|t Journal of Clinical Medicine
|v 11
|x 2077-0383
|y 2021
909 C O |o oai:inrepo02.dkfz.de:178459
|p VDB
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)2b12a7cfc604eb9816670e995f7af508
|a Deutsches Krebsforschungszentrum
|b 2
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF4-312
|1 G:(DE-HGF)POF4-310
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Krebsforschung
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2021
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b J CLIN MED : 2019
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0320
|2 StatID
|a DBCoverage
|b PubMed Central
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0501
|2 StatID
|a DBCoverage
|b DOAJ Seal
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0500
|2 StatID
|a DBCoverage
|b DOAJ
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b DOAJ : Blind peer review
|d 2021-05-04
915 _ _ |0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|a Creative Commons Attribution CC BY (No Version)
|b DOAJ
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0600
|2 StatID
|a DBCoverage
|b Ebsco Academic Search
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b ASC
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)1110
|2 StatID
|a DBCoverage
|b Current Contents - Clinical Medicine
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)9900
|2 StatID
|a IF < 5
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0561
|2 StatID
|a Article Processing Charges
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0700
|2 StatID
|a Fees
|d 2021-05-04
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21